What is new in the pathogenesis and treatment of IgA glomerulonephritis

doi:10.5527/wjn.v13.i4.98709

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3079)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

HTML

1873

Figures (1-4)

206

Tables (1-4)

237

Sum=2368

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

100

Download

224

Sum=324

Publishing Process of This Article

Item

Count

Browse

Download

127

Sum=160

Dec 25, 2024 (publication date) through Mar 31, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Nephrol. Dec 25, 2024; 13(4): 98709
Published online Dec 25, 2024. doi: 10.5527/wjn.v13.i4.98709

Full Size Figure Download Figure

Figure 4 Treatment for IgA nephropathy. SGLT2: Sodium-glucose cotransporter; MRA: Mineralocorticoid receptor antagonists; GLP-1: Glucagon-like peptide-1; CKD: Chronic kidney disease; DEARA: Dual endothelial angiotensin receptor antagonist.

Citation: Salvadori M, Rosso G. What is new in the pathogenesis and treatment of IgA glomerulonephritis. World J Nephrol 2024; 13(4): 98709
URL: https://www.wjgnet.com/2220-6124/full/v13/i4/98709.htm
DOI: https://dx.doi.org/10.5527/wjn.v13.i4.98709